The atmosphere at the FDA’s White Oak Campus in Silver Spring, Maryland, was eerily quiet for a Thursday afternoon. For Dr. Marty Makary, the agency’s commissioner, the silence may have been a symptom of a depleted workforce—following cuts by the Department of Government Efficiency (DOGE) that eliminated roughly 3,500 positions—or perhaps a reflection of his own precarious standing. During a scheduled 90-minute interview with Men’s Health, a single 15-minute phone call disrupted the flow, leaving Makary looking “ashen” and leading the press liaison to abruptly end the session.
By Tuesday, the instability became official: Makary offered his resignation. What began as a profile of a reformer became an unintentional exit interview for a man tasked with a nearly impossible mandate. Makary was hired to bridge the gap between the FDA’s rigid, “old guard” scientific establishment and the populist, often provocative health goals of the Make America Healthy Again (MAHA) movement led by HHS Secretary Robert F. Kennedy Jr.
As a board-certified physician, I have watched the tension between clinical dogma and emerging patient-centric data for years. Makary’s tenure was a lightning rod for this conflict. He sought to accelerate the approval of life-saving cures for cancer and deafness while simultaneously questioning the “priesthood” of medical journals and the centralization of authority at the NIH. Yet, the friction of governance eventually won out. The final straw reportedly came over the approval of flavored vapes; while Makary resisted authorizing menthol, mango, and blueberry flavors due to concerns over underage use, the Trump administration insisted on their authorization, effectively undermining his authority.
The War on Medical Dogma
Throughout his career as a pioneering oncologist and surgeon, Makary has positioned himself as a contrarian, though he prefers the term “observant.” He argues that medicine has become too centralized, with a small circle of editors and elites deciding what constitutes a breakthrough. During his conversation with Men’s Health, Makary detailed his efforts to dismantle what he calls “medical dogma,” particularly regarding hormonal health and nutrition.
One of the most contentious areas of his tenure involved testosterone replacement therapy (TRT) and peptides. Makary pushed for a more objective evaluation of TRT, arguing that the stigma surrounding it—a hangover from Olympic scandals of the 1980s—has inhibited legitimate treatment for men with symptomatic low testosterone. He pointed to the more mature body of research on hormone replacement for menopausal women as a blueprint for how the agency should approach male hormonal depletion.
On peptides, Makary navigated a delicate line between political pressure and scientific rigor. While Secretary Kennedy expressed a desire to end the “war on peptides,” Makary remained cautious, noting that while amino acids are generally safe, the field “desperately needs” high-quality, placebo-controlled trials before sweeping safety declarations can be made.
Shifting the Nutritional Paradigm
Beyond pharmaceuticals, Makary targeted the FDA’s approach to the American diet. He argued that the traditional “calories in vs. Calories out” model is a failure because it ignores the hormonal impact of ultra-processed foods. He compared certain food additives to medications like prednisone, which can trigger metabolic shifts and disrupt the body’s fullness feedback loop, making weight gain a biological inevitability rather than a failure of willpower.
To illustrate the shift in thinking he championed at the agency, the following table outlines the contrast between traditional FDA-aligned health narratives and the MAHA-influenced approach Makary supported:
| Health Focus | Traditional “Old Guard” View | Makary/MAHA Perspective |
|---|---|---|
| Nutrition | Focus on fat reduction and caloric deficits. | Focus on ultra-processed foods and microbiome health. |
| Drug Approval | Rigid, multi-year randomized control trials. | Accelerated “record speed” paths for terminal illness. |
| Hormones | High caution/stigma regarding TRT. | Objective, symptom-based hormone replacement. |
| Public Health | Unified, centralized agency messaging. | Transparent, decentralized, and debated data. |
The ‘Third Culture’ Skeptic
To understand Makary’s approach to the FDA, one must look at his upbringing. Born in Liverpool and raised in Pennsylvania by parents who grew up with state-controlled television in Egypt, Makary describes himself as a “third culture kid.” This background instilled in him a fundamental skepticism of government narratives—a trait he views as a professional asset in medical research.
This skepticism defined his response to the COVID-19 pandemic. Makary was an early voice warning of the virus’s arrival, but he later became a fierce critic of the CDC and Dr. Anthony Fauci. He specifically cited the closure of schools in 2021 as an “injustice,” arguing that the lowest-risk population—children—suffered the harshest restrictions due to a “myopic focus” on viral transmission over general well-being.
Despite the polarization, Makary maintained that his goal was to find common ground. He highlighted his bipartisan Senate confirmation as evidence that issues like hospital price transparency and patient safety could unite a fractured political landscape. He viewed his role not as a politician, but as a physician attempting to “lower the temperature” by providing data-driven answers to questions that many Americans felt were being ignored by the establishment.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
With Makary’s departure, the FDA enters a period of transition. President Trump has appointed Kyle Diamantas to serve as Acting Commissioner. The agency now faces the challenge of maintaining scientific integrity while continuing the push for the “modernization” and deregulation championed by the MAHA movement. The coming months will reveal whether Makary’s attempts to accelerate drug approvals and overhaul nutritional guidelines will be sustained or rolled back under new leadership.
What are your thoughts on the balance between regulatory safety and the need for faster medical innovation? Share your perspective in the comments below.
